The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients

Neurobiology of Aging

Volumn 33, Issue 9, 2012, Pages 2160-2171

  Mann, Amandeep ^a   Miksys, Sharon L ^a   Gaedigk, Andrea ^b   Kish, Stephen J ^a   Mash, Deborah C ^c   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; CNS drugs; CYP2D6; Human brain; Parkinson's disease

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; AGE; AGED; ALLELE; ARTICLE; BRAIN LEVEL; CAUDATE NUCLEUS; CEREBELLUM; CHILD; CLINICAL ARTICLE; COMPARATIVE ANATOMY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ANALYSIS; ENZYME LOCALIZATION; FEMALE; FETUS; FRONTAL CORTEX; GENETIC ASSOCIATION; GENOTYPE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFANT; MALE; ONTOGENY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SUBSTANTIA NIGRA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BRAIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2D6; FEMALE; FETUS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PARKINSON DISEASE; POSTMORTEM CHANGES; YOUNG ADULT;

EID: 84859065441     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.08.014     Document Type: Article

References (47)

1. Alcorn J., McNamara P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin. Pharmacokinet 2002, 41:1077-1094.
2. Alves G., Kurz M., Lie S.A., Larsen J.P. Cigarette smoking in Parkinson's disease: influence on disease progression. Mov. Disord 2004, 19:1087-1092.
3. Bialecka M., Klodowska-Duda G., Honczarenko K., Gawrońska-Szklarz B., Opala G., Safranow K., Droüdzik M. Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), n-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease. Parkinsonism Relat. Disord 2007, 13:224-229.
4. Bromek E., Haduch A., Daniel W.A. The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study. Eur. J. Pharmacol 2010, 626:171-178.
5. De Gregori M., Allegri M., De Gregori S., Garbin G., Tinelli C., Regazzi M., Govoni S., Ranzani G.n. How and Why to Screen for CYP2D6 Interindividual Variability in Patients Under Pharmacological Treatments. Curr. Drug Metab 2010, 11:276-282.
6. Deng Y., Newman B., Dunne M.P., Silburn P.A., Mellick G.D. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann. Neurol 2004, 55:897.
7. Elbaz A., Levecque C., Clavel J., Vidal J.S., Richard F., Amouyel P., Alpérovitch A., Chartier-Harlin M.C., Tzourio C. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann. Neurol 2004, 55:430-434.
8. Gaedigk A., Bradford L.D., Alander S.W., Leeder J.S. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab. Dispos 2006, 34:563-569.
9. Gaedigk A., Fuhr U., Johnson C., Bérard L.A., Bradford D., Leeder J.S. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 2010, 11:43-53.
10. Gaedigk A., Ndjountché L., Divakaran K., Dianne Bradford L., Zineh I., Oberlander T.F., Brousseau D.C., McCarver D.G., Johnson J.A., Alander S.W., Wayne Riggs K., Steven Leeder J. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther 2007, 81:242-251.
11. Gaedigk A., Simon S.D., Pearce R.E., Bradford L.D., Kennedy M.J., Leeder J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther 2008, 83:234-242.
12. Grosset G.D., Grosset K.A., Okun S.M., Fernandez H.H. Parkinson's Disease Clinicians Desk Reference 2009, Manson Publishing, Ltd., London.
13. Haduch A., Bromek E., Daniel W.A. The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain. Eur. J. Pharmacol 2011, 651:51-58.
14. Haduch A., Wójcikowski J., Daniel W.A. Effects of chronic treatment with classic and newer antidepressants and neuroleptics on the activity and level of CYP2D in the rat brain. Pol. J. Pharmacol 2004, 56:857-862.
15. Halling J., Petersen M.S., Grandjean P., Weihe P., Brosen K. Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands. Pharmacogenet. Genomics 2008, 18:209-212.
16. Hedlund E., Wyss A., Kainu T., Backlund M., Köhler C., Pelto-Huikko M., Gustafsson J.A., Warner M. Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene. Mol. Pharmacol 1996, 50:342-350.
17. Hernandez D.G., Nalls M.A., Gibbs J.R., Arepalli S., van der Brug M., Chong S., Moore M., Longo D.L., Cookson M.R., Traynor B.J., Singleton A.B. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum. Mol. Genet 2010, 20:1164-1172.
18. Hindle J.V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010, 39:156-161.
19. Hiroi T., Imaoka S., Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun 1998, 249:838-843.
20. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
21. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
22. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther 2007, 116:496-526.
23. Kessler R.C., Amminger G.P., Aguilar-Gaxiola S., Alonso J., Lee S., Ustün T.B. Age of onset of mental disorders: a review of recent literature. Curr. Opin. Psychiatry 2007, 20:359-364.
24. Kokhar J.Y., Tyndale R.F. Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuropsychopharmacology 2011, 36:692-700.
25. Kurokohchi K., Yoneyama H., Matsuo Y., Nishioka M., Ichikawa Y. Effects of interleukin 1 alpha on the activities and gene expressions of the cytochrome P450IID subfamily. Biochem. Pharmacol 1992, 44:1669-1674.
26. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med 1998, 339:1044-1053.
27. Mann A., Miksys S., Lee A., Mash D.C., Tyndale R.F. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 2008, 55:1147-1155.
28. Mann A., Tyndale R.F. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. Eur. J. Neurosci 2010, 31:1185-1193.
29. Marek K., Jennings D., Seibyl J. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann. Neurol 2003, 53(Suppl 3):S160-S166. Discussion, S166-S169.
30. Matoh n., Tanaka S., Takehashi M., Banasik M., Stedeford T., Masliah E., Suzuki S., Nishimura Y., Ueda K. Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells. Gene Expr 2003, 11:117-124.
31. McCann S.J., Pond S.M., James K.M., Le Couteur D.G. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Sci 1997, 153:50-53.
32. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord 2008, 23:474-483.
33. Mena M.A., García de Yébenes J. Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia. Neuroscientist 2008, 14:544-560.
34. Miksys S., Rao Y., Hoffmann E., Mash D.C., Tyndale R.F. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J. Neurochem 2002, 82:1376-1387.
35. Miksys S., Tyndale R.F. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab. Rev 2004, 36:313-333.
36. Modi S., Gilham D.E., Sutcliffe M.J., Lian L.Y., Primrose W.U., Wolf C.R., Roberts G.C. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 1997, 36:4461-4470.
37. Nelson J.C., Mazure C.M., Jatlow P.I. Desipramine treatment of major depression in patients over 75 years of age. J. Clin. Psychopharmacol 1995, 15:99-105.
38. Piguet O., Double K.L., Kril J.J., Harasty J., Macdonald V., McRitchie D.A., Halliday G.M. White matter loss in healthy ageing: a postmortem analysis. Neurobiol. Aging 2009, 30:1288-1295.
39. Singh M., Khanna V.K., Shukla R., Parmar D. Association of polymorphism in cytochrome P450 2D6 and n-acetyltransferase-2 with Parkinson's disease. Dis. Markers 2010, 28:87-93.
40. Stevens J.C., Marsh S.A., Zaya M.J., Regina K.J., Divakaran K., Le M., Hines R.n. Developmental changes in human liver CYP2D6 expression. Drug Metab. Dispos 2008, 36:1587-1593.
41. Suzuki T., Fujita S., Narimatsu S., Masubuchi Y., Tachibana M., Ohta S., Hirobe M. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. FASEB J 1992, 6:771-776.
42. Thompson R.F., Atzmon G., Gheorghe C., Liang H.Q., Lowes C., Greally J.M., Barzilai n. Tissue-specific dysregulation of DNA methylation in aging. Aging Cell 2010, 9:506-518.
43. Treluyer J.M., Jacqz-Aigrain E., Alvarez F., Cresteil T. Expression of CYP2D6 in developing human liver. Eur. J. Biochem 1991, 202:583-588.
44. Tyndale R.F., Li Y., Li n.Y., Messina E., Miksys S., Sellers E.M. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab. Dispos 1999, 27:924-930.
45. Wang B., Yang L.P., Zhang X.Z., Huang S.Q., Bartlam M., Zhou S.F. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab. Rev 2009, 41:573-643.
46. Yu A.M., Idle J.R., Krausz K.W., Küpfer A., Gonzalez F.J. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J. Pharmacol. Exp. Ther 2003, 305:315-322.
47. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol 2004, 369:23-37.